Liquidia (NASDAQ:LQDA) Upgraded to Strong-Buy by Raymond James

Raymond James upgraded shares of Liquidia (NASDAQ:LQDA) from an outperform rating to a strong-buy rating in a research report released on Monday morning, Marketbeat Ratings reports.

A number of other equities analysts have also weighed in on LQDA. HC Wainwright reaffirmed a buy rating and issued a $32.00 price objective on shares of Liquidia in a research note on Wednesday, July 10th. Needham & Company LLC reaffirmed a buy rating and set a $25.00 price objective on shares of Liquidia in a report on Monday. Finally, Oppenheimer assumed coverage on shares of Liquidia in a research report on Tuesday, June 25th. They set a market perform rating on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and an average price target of $23.14.

Liquidia Stock Performance

Shares of Liquidia stock opened at $9.98 on Monday. The company has a fifty day moving average of $11.99 and a 200 day moving average of $13.27. The company has a market capitalization of $762.61 million, a P/E ratio of -6.40 and a beta of 0.32. Liquidia has a fifty-two week low of $5.71 and a fifty-two week high of $16.99.

Insiders Place Their Bets

In other news, CEO Roger Jeffs sold 8,053 shares of the stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $12.53, for a total transaction of $100,904.09. Following the completion of the transaction, the chief executive officer now directly owns 818,932 shares in the company, valued at approximately $10,261,217.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Michael Kaseta sold 3,906 shares of Liquidia stock in a transaction dated Friday, July 12th. The stock was sold at an average price of $12.53, for a total value of $48,942.18. Following the completion of the transaction, the chief financial officer now owns 312,389 shares in the company, valued at $3,914,234.17. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Roger Jeffs sold 8,053 shares of the company’s stock in a transaction that occurred on Friday, July 12th. The shares were sold at an average price of $12.53, for a total value of $100,904.09. Following the sale, the chief executive officer now owns 818,932 shares in the company, valued at $10,261,217.96. The disclosure for this sale can be found here. Insiders have sold a total of 21,437 shares of company stock valued at $268,549 in the last quarter. 31.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Liquidia

Several large investors have recently modified their holdings of the stock. American International Group Inc. lifted its position in Liquidia by 5.2% in the first quarter. American International Group Inc. now owns 24,806 shares of the company’s stock worth $366,000 after buying an additional 1,215 shares during the last quarter. Arizona State Retirement System lifted its holdings in shares of Liquidia by 10.7% in the 2nd quarter. Arizona State Retirement System now owns 13,842 shares of the company’s stock worth $166,000 after acquiring an additional 1,341 shares during the last quarter. Bleakley Financial Group LLC boosted its stake in shares of Liquidia by 6.6% during the 1st quarter. Bleakley Financial Group LLC now owns 33,250 shares of the company’s stock worth $490,000 after purchasing an additional 2,057 shares during the period. Quest Partners LLC bought a new position in Liquidia during the 2nd quarter valued at about $27,000. Finally, Hilltop National Bank purchased a new stake in Liquidia in the 2nd quarter worth about $33,000. Institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).